Oops, you're using an old version of your browser so some of the features on this page may not be displaying properly.
MINIMAL Requirements: Google Chrome 24+, Mozilla Firefox 20+, Internet Explorer 11, Opera 15–18, Apple Safari 7, SeaMonkey 2.15-2.23
Joining forces in action
The Rare Cancers Working Group (RCWG), 36 partner strong multi-stakeholder partnership, founded in 2008 and coordinated by the European Society for Medical Oncology (ESMO), brings together scientific societies, patient and research organizations, healthcare and education providers, and the industry.
24% of all new cancer diagnoses, including all paediatric cancers, are rare forms of the disease. With 650,000 new rare cancer diagnoses annually and around 5.1 million people in the EU living with a rare cancer, rare cancers are not so rare.
Despite the EU’s many achievements, the very nature of rare cancers adds a layer of complexity to overcoming the challenges they pose to patients, the researchers and the healthcare professionals who research and treat them. Thus, all policies at the EU level should to take into account the specificities of rare cancers to provide the best possible care to all patients.
ESMO’s Rare Cancers Working Group (RCWG) continues its work to secure the prioritisation of rare cancers on the global and European healthcare agendas and provided feedback on the European Economic and Social Committee’s (EESC)
ESMO Director of Public Policy, Professor Jean-Yves Blay, speaks to leading media outlet Euractiv ahead of the EU 2024 elections about the role of oncologists in delivering Europe’s Beating Cancer Plan during the new EU mandate and the upcoming Hungarian EU Presidency
The European Society for Medical Oncology’s (ESMO) Rare Cancers Working Group (RCWG) is a multi-stakeholder partnership which brings together scientific societies, patient and research organisations, healthcare and education providers, and industry
The webinar brought together speakers from EU institutions, European Reference Networks, scientific societies, patient organisations, industry and other crucial stakeholders to discuss the challenges the community is facing and potential solutions.
This site uses cookies. Some of these cookies are essential, while others help us improve your experience by providing insights into how the site is being used.
For more detailed information on the cookies we use, please check our Privacy Policy.
Necessary cookies enable core functionality. The website cannot function properly without these cookies, and you can only disable them by changing your browser preferences.
